Cortexyme Selects 3CLpro Inhibitor As COVID-19 Candidate

by Vandana Singh, Benzinga Editor

July 23, 2021 9:50 AM | 28 seconds read | Make a Comment

Cortexyme Inc CRTX has selected COR803 to further evaluate for coronavirus infections, including COVID-19 disease.
COR803 is a novel patent-pending small molecule 3CLpro inhibitor, and 3CLpro (Mpro) is a validated antiviral drug target shown to be essential in viral replication of SARS-CoV-2.
The company is advancing its disease-modifying GAIN Trial in mild to moderate Alzheimer's disease, with top-line data expected in Q4 of 2021.
Price Action: CRTX shares are up 1.02% at $65.15 during the market session on the last check Friday.

Posted In: Biotech News Health Care Small Cap General Briefs

Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.